Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Aug;68(2):240–250. doi: 10.1038/bjc.1993.322

In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.

K J Mellish 1, L R Kelland 1, K R Harrap 1
PMCID: PMC1968570  PMID: 8347478

Abstract

The platinum drug chemosensitivity of five human cervical squamous cell carcinoma cell lines (HX/151, HX/155, HX/156, HX/160 and HX/171) derived from previously untreated patients has been determined. Compared to our data obtained previously using human ovarian carcinoma cell lines, all five lines were relatively resistant to cisplatin, carboplatin, iproplatin and tetraplatin. One of the lines (HX/156) was exceptionally sensitive to the novel platinum (IV) ammine/amine dicarboxylates JM216 [bis-acetatoammine dichloro (cyclohexylamine) platinum (IV)] and JM221 [ammine dibutyrato dichloro (cyclohexylamine) platinum (IV)]. The range in IC50 values across the five lines was approximately 2.5-fold for cisplatin, carboplatin and iproplatin, 13-fold for tetraplatin and JM216, and 25-fold for JM221. No significant correlation (P > 0.05) was observed between platinum drug chemosensitivity and either glutathione levels or cadmium chloride sensitivity, an indicator of metallothionein levels. In addition, there was no significant correlation (P > 0.05) between cisplatin cytotoxicity and intracellular cisplatin accumulation or JM216 cytotoxicity and intracellular JM216 accumulation over the dose range 5-100 microM (2 h exposure). The exceptional sensitivity of HX/156 to JM216 appears, at least partially, to be a result of enhanced accumulation of JM216. An 8.6-fold acquired cisplatin resistant stable variant of HX/155 has been generated in vitro. Intracellular cisplatin accumulation was reduced by 2.4 +/- 0.3-fold (mean +/- s.d.) in HX/155cisR across the dose range 1-100 microM (2 h exposure). Glutathione levels in HX/155cisR were elevated by 1.3-fold in terms of protein content and by 1.6-fold in terms of cell number. HX/155cisR was 1.9-fold resistant to cadmium chloride. Total platinum bound to DNA after cisplatin exposure (10, 25, 50 or 100 microM for 2 h) was 3.6 +/- 0.6-fold (mean +/- s.d.) lower in HX/155cisR. Hence the mechanism of acquired cisplatin resistance in HX/155cisR appears to be multifocal, with reduced intracellular drug accumulation and elevated glutathione and metallothionein levels combining to reduce DNA platination levels. While HX/155cisR was cross-resistant to tetraplatin and carboplatin, novel platinum (II) and (IV) ammine/amine complexes, including JM216 and JM221, partially circumvented resistance (resistance factors of 1.5-2). Non cross-resistance was observed to iproplatin and nine non-platinum anticancer agents. Intracellular tetraplatin accumulation was reduced by 1.8 +/- 0.1-fold (mean +/- s.d.) in HX/155cisR across the dose range 1-100 microM (2 h exposure). In contrast, after JM216 exposure (1-100 microM for 2 h), no significant difference in intracellular platinum levels between HX/155 and HX/155cisR was observed.(ABSTRACT TRUNCATED AT 400 WORDS)

Full text

PDF
245

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberts D. S., Garcia D., Mason-Liddil N. Cisplatin in advanced cancer of the cervix: an update. Semin Oncol. 1991 Feb;18(1 Suppl 3):11–24. [PubMed] [Google Scholar]
  2. Alberts D. S., Mason-Liddil N. The role of cisplatin in the management of advanced squamous cell cancer of the cervix. Semin Oncol. 1989 Aug;16(4 Suppl 6):66–78. [PubMed] [Google Scholar]
  3. Anderson W. K., Quagliato D. A., Haugwitz R. D., Narayanan V. L., Wolpert-DeFilippes M. K. Synthesis, physical properties, and antitumor activity of tetraplatin and related tetrachloroplatinum(IV) stereoisomers of 1,2-diaminocyclohexane. Cancer Treat Rep. 1986 Aug;70(8):997–1002. [PubMed] [Google Scholar]
  4. Andrews P. A., Howell S. B. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells. 1990 Feb;2(2):35–43. [PubMed] [Google Scholar]
  5. Andrews P. A., Murphy M. P., Howell S. B. Characterization of cisplatin-resistant COLO 316 human ovarian carcinoma cells. Eur J Cancer Clin Oncol. 1989 Apr;25(4):619–625. doi: 10.1016/0277-5379(89)90195-8. [DOI] [PubMed] [Google Scholar]
  6. Andrews P. A., Murphy M. P., Howell S. B. Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res. 1985 Dec;45(12 Pt 1):6250–6253. [PubMed] [Google Scholar]
  7. Andrews P. A., Schiefer M. A., Murphy M. P., Howell S. B. Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion. Chem Biol Interact. 1988;65(1):51–58. doi: 10.1016/0009-2797(88)90030-0. [DOI] [PubMed] [Google Scholar]
  8. Andrews P. A., Velury S., Mann S. C., Howell S. B. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res. 1988 Jan 1;48(1):68–73. [PubMed] [Google Scholar]
  9. BURTON K. A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J. 1956 Feb;62(2):315–323. doi: 10.1042/bj0620315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Behrens B. C., Hamilton T. C., Masuda H., Grotzinger K. R., Whang-Peng J., Louie K. G., Knutsen T., McKoy W. M., Young R. C., Ozols R. F. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res. 1987 Jan 15;47(2):414–418. [PubMed] [Google Scholar]
  11. Bungo M., Fujiwara Y., Kasahara K., Nakagawa K., Ohe Y., Sasaki Y., Irino S., Saijo N. Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair. Cancer Res. 1990 May 1;50(9):2549–2553. [PubMed] [Google Scholar]
  12. Canon J. L., Humblet Y., Symann M. Resistance to cisplatin: how to deal with the problem? Eur J Cancer. 1990 Jan;26(1):1–3. doi: 10.1016/0277-5379(90)90247-q. [DOI] [PubMed] [Google Scholar]
  13. Chao C. C., Lee Y. L., Cheng P. W., Lin-Chao S. Enhanced host cell reactivation of damaged plasmid DNA in HeLa cells resistant to cis-diamminedichloroplatinum(II). Cancer Res. 1991 Jan 15;51(2):601–605. [PubMed] [Google Scholar]
  14. Eastman A. Cross-linking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes. Chem Biol Interact. 1987 Mar;61(3):241–248. doi: 10.1016/0009-2797(87)90004-4. [DOI] [PubMed] [Google Scholar]
  15. Fram R. J., Woda B. A., Wilson J. M., Robichaud N. Characterization of acquired resistance to cis-diamminedichloroplatinum (II) in BE human colon carcinoma cells. Cancer Res. 1990 Jan 1;50(1):72–77. [PubMed] [Google Scholar]
  16. Godwin A. K., Meister A., O'Dwyer P. J., Huang C. S., Hamilton T. C., Anderson M. E. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3070–3074. doi: 10.1073/pnas.89.7.3070. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Gore M. E., Fryatt I., Wiltshaw E., Dawson T., Robinson B. A., Calvert A. H. Cisplatin/carboplatin cross-resistance in ovarian cancer. Br J Cancer. 1989 Nov;60(5):767–769. doi: 10.1038/bjc.1989.356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Griffith O. W. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem. 1980 Jul 15;106(1):207–212. doi: 10.1016/0003-2697(80)90139-6. [DOI] [PubMed] [Google Scholar]
  19. Hamilton T. C., Winker M. A., Louie K. G., Batist G., Behrens B. C., Tsuruo T., Grotzinger K. R., McKoy W. M., Young R. C., Ozols R. F. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol. 1985 Jul 15;34(14):2583–2586. doi: 10.1016/0006-2952(85)90551-9. [DOI] [PubMed] [Google Scholar]
  20. Harrap K. R., Jones M., Siracky J., Pollard L. A., Kelland L. R. The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs. Ann Oncol. 1990;1(1):65–76. doi: 10.1093/oxfordjournals.annonc.a057678. [DOI] [PubMed] [Google Scholar]
  21. Hill B. T., Shellard S. A., Hosking L. K., Dempke W. C., Fichtinger-Schepman A. M., Tone T., Scanlon K. J., Whelan R. D. Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexate. Cancer Res. 1992 Jun 1;52(11):3110–3118. [PubMed] [Google Scholar]
  22. Hills C. A., Kelland L. R., Abel G., Siracky J., Wilson A. P., Harrap K. R. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer. 1989 Apr;59(4):527–534. doi: 10.1038/bjc.1989.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Hospers G. A., Mulder N. H., de Jong B., de Ley L., Uges D. R., Fichtinger-Schepman A. M., Scheper R. J., de Vries E. G. Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro. Cancer Res. 1988 Dec 1;48(23):6803–6807. [PubMed] [Google Scholar]
  24. Hrubisko M., McGown A. T., Fox B. W. The role of metallothionein, glutathione, glutathione S-transferases and DNA repair in resistance to platinum drugs in a series of L1210 cell lines made resistant to anticancer platinum agents. Biochem Pharmacol. 1993 Jan 7;45(1):253–256. doi: 10.1016/0006-2952(93)90399-h. [DOI] [PubMed] [Google Scholar]
  25. Kelland L. R., Burgess L., Steel G. G. Characterization of four new cell lines derived from human squamous carcinomas of the uterine cervix. Cancer Res. 1987 Sep 15;47(18):4947–4952. [PubMed] [Google Scholar]
  26. Kelland L. R., Jones M., Abel G., Valenti M., Gwynne J., Harrap K. R. Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery. Cancer Chemother Pharmacol. 1992;30(1):43–50. doi: 10.1007/BF00686484. [DOI] [PubMed] [Google Scholar]
  27. Kelland L. R., Mistry P., Abel G., Freidlos F., Loh S. Y., Roberts J. J., Harrap K. R. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line. Cancer Res. 1992 Apr 1;52(7):1710–1716. [PubMed] [Google Scholar]
  28. Kelland L. R., Mistry P., Abel G., Loh S. Y., O'Neill C. F., Murrer B. A., Harrap K. R. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Cancer Res. 1992 Jul 15;52(14):3857–3864. [PubMed] [Google Scholar]
  29. Kelland L. R., Tonkin K. S. In vitro chemosensitivity of four new carcinoma of the cervix cell lines: relationship to radiosensitivity. Eur J Cancer Clin Oncol. 1989 Aug;25(8):1211–1218. doi: 10.1016/0277-5379(89)90417-3. [DOI] [PubMed] [Google Scholar]
  30. Kelley S. L., Basu A., Teicher B. A., Hacker M. P., Hamer D. H., Lazo J. S. Overexpression of metallothionein confers resistance to anticancer drugs. Science. 1988 Sep 30;241(4874):1813–1815. doi: 10.1126/science.3175622. [DOI] [PubMed] [Google Scholar]
  31. Kelley S. L., Rozencweig M. Resistance to platinum compounds: mechanisms and beyond. Eur J Cancer Clin Oncol. 1989 Aug;25(8):1135–1140. doi: 10.1016/0277-5379(89)90405-7. [DOI] [PubMed] [Google Scholar]
  32. Kikuchi Y., Iwano I., Miyauchi M., Kita T., Sugita M., Tenjin Y., Nagata I. Possible mechanisms of resistance to cis-diamminedichloroplatinum (II) of human ovarian cancer cells. Jpn J Cancer Res. 1990 Jun-Jul;81(6-7):701–706. doi: 10.1111/j.1349-7006.1990.tb02630.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Kirby K. S., Cook E. A. Isolation of deoxyribonucleic acid from mammalian tissues. Biochem J. 1967 Jul;104(1):254–257. doi: 10.1042/bj1040254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Kuppen P. J., Schuitemaker H., van 't Veer L. J., de Bruijn E. A., van Oosterom A. T., Schrier P. I. cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines. Cancer Res. 1988 Jun 15;48(12):3355–3359. [PubMed] [Google Scholar]
  35. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  36. Lewis A. D., Hayes J. D., Wolf C. R. Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects. Carcinogenesis. 1988 Jul;9(7):1283–1287. doi: 10.1093/carcin/9.7.1283. [DOI] [PubMed] [Google Scholar]
  37. Loh S. Y., Mistry P., Kelland L. R., Abel G., Harrap K. R. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. Br J Cancer. 1992 Dec;66(6):1109–1115. doi: 10.1038/bjc.1992.419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Mangioni C., Bolis G., Pecorelli S., Bragman K., Epis A., Favalli G., Gambino A., Landoni F., Presti M., Torri W. Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst. 1989 Oct 4;81(19):1464–1471. doi: 10.1093/jnci/81.19.1464. [DOI] [PubMed] [Google Scholar]
  39. Masuda H., Ozols R. F., Lai G. M., Fojo A., Rothenberg M., Hamilton T. C. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res. 1988 Oct 15;48(20):5713–5716. [PubMed] [Google Scholar]
  40. Masuda H., Tanaka T., Matsuda H., Kusaba I. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res. 1990 Mar 15;50(6):1863–1866. [PubMed] [Google Scholar]
  41. McGuire W. P., 3rd, Arseneau J., Blessing J. A., DiSaia P. J., Hatch K. D., Given F. T., Jr, Teng N. N., Creasman W. T. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1989 Oct;7(10):1462–1468. doi: 10.1200/JCO.1989.7.10.1462. [DOI] [PubMed] [Google Scholar]
  42. Mistry P., Kelland L. R., Abel G., Sidhar S., Harrap K. R. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer. 1991 Aug;64(2):215–220. doi: 10.1038/bjc.1991.279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Pinto A. L., Lippard S. J. Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. Biochim Biophys Acta. 1985;780(3):167–180. doi: 10.1016/0304-419x(85)90001-0. [DOI] [PubMed] [Google Scholar]
  44. Russell J. M., Blair V., Hunter R. D. Cervical carcinoma: prognosis in younger patients. Br Med J (Clin Res Ed) 1987 Aug 1;295(6593):300–303. doi: 10.1136/bmj.295.6593.300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J. T., Bokesch H., Kenney S., Boyd M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990 Jul 4;82(13):1107–1112. doi: 10.1093/jnci/82.13.1107. [DOI] [PubMed] [Google Scholar]
  46. Smales E., Perry C. M., Ashby M. A., Baker J. W. The influence of age on prognosis in carcinoma of the cervix. Br J Obstet Gynaecol. 1987 Aug;94(8):784–787. doi: 10.1111/j.1471-0528.1987.tb03727.x. [DOI] [PubMed] [Google Scholar]
  47. Teicher B. A., Holden S. A., Herman T. S., Sotomayor E. A., Khandekar V., Rosbe K. W., Brann T. W., Korbut T. T., Frei E., 3rd Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II). Int J Cancer. 1991 Jan 21;47(2):252–260. doi: 10.1002/ijc.2910470214. [DOI] [PubMed] [Google Scholar]
  48. Teicher B. A., Holden S. A., Kelley M. J., Shea T. C., Cucchi C. A., Rosowsky A., Henner W. D., Frei E., 3rd Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res. 1987 Jan 15;47(2):388–393. [PubMed] [Google Scholar]
  49. de Graeff A., Slebos R. J., Rodenhuis S. Resistance to cisplatin and analogues: mechanisms and potential clinical implications. Cancer Chemother Pharmacol. 1988;22(4):325–332. doi: 10.1007/BF00254240. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES